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ABSTRACT
Radiation therapy for cancer in the head and neck region leads to a marked loss of salivary
gland parenchyma, resulting in a severe reduction of salivary secretions. Currently, there is
no satisfactory treatment for these patients. To address this problem, we are using both tis-
sue engineering and gene transfer principles to develop an orally implantable, artificial fluid-
secreting device. In the present study, we examined the tissue compatibility of two biodegrad-
able substrata potentially useful in fabricating such a device. We implanted in Balb/c mice
tubular scaffolds of poly-L-lactic acid (PLLA), poly-glycolic acid coated with PLLA
(PGA/PLLA), or nothing (sham-operated controls) either beneath the skin on the back, a
site widely used in earlier toxicity and biocompatibility studies, or adjacent to the buccal
mucosa, a site quite different functionally and immunologically. At 1, 3, 7, 14, and 28 days
postimplantation, implant sites were examined histologically, and systemic responses were
assessed by conventional clinical chemistry and hematology analyses. Inflammatory re-
sponses in the connective tissue were similar regardless of site or type of polymer implant
used. However, inflammatory reactions were shorter and without epithelioid and giant cells
in sham-operated controls. Also, biodegradation proceeded more slowly with the PLLA
tubules than with the PGA/PLLA tubules. No significant changes in clinical chemistry and
hematology were seen due to the implantation of tubular scaffolds. These results indicate
that the tissue responses to PLLA and PGA/PLLA scaffolds are generally similar in areas
subjacent to skin in the back and oral cavity. However, these studies also identified several
potentially significant concerns that must be addressed prior to initiating any clinical ap-
plications of this device.
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INTRODUCTION
EXTREME SALIVA RY HYPOFUNCTION is a common side effect caused by radiation therapy for cancer inthe head and neck region. If the therapeutic radiation treatment exceeds ,50 Gy, generally irre-
versible damage occurs to the salivary glands.1 Indeed, recent studies suggest that a mean dose of 26
Gy should be the planning goal if substantial sparing of salivary glands in the radiation field is desired.2
Salivary gland damage leads to persistent hypofunction with marked reductions in salivary output.3 Un-
fortunately, at present, there is no satisfactory treatment for this condition. Affected patients suffer from
rampant dental caries, frequent mucosal infections, and dysphagia, as well as considerable pain and dis-
comfort, all of which significantly decrease their quality of life.
We recently initiated an effort to develop an artificial salivary gland device utilizing tissue engi-
neering combined with gene transfer methodology.4–6 This device as initially designed consists of a
blind end tube fabricated from a biodegradable polymer, coated with a suitable extracellular matrix pro-
tein, and lined on its lumen by a monolayer of epithelial cells capable of unidirectional fluid secretion.6
An important consideration toward the in vivo application of such a device is tissue compatibility. Many
previous studies have employed tissue engineering approaches to replace a variety of tubular tissue
structures, including intestine,7 blood vessels,8 ureters,9 and trachea.10 However, there have been no at-
tempts to study such structures in the orofacial region.
Poly-L-lactic acid (PLLA) and poly-glycolic acid (PGA) have been used in medical devices for over
30 years and are generally considered as biocompatible.11–13 This suggested to us that tubular struc-
tures made of these materials might be suitable for use in the development of an artificial salivary gland.6
In order to test this possibility, we compared the tissue compatibility of tubules made of PLLA, or of
PGA coated with PLLA, at two sites. One site, subjacent to the skin on the back, has been widely used
in earlier studies by others for examining tissue compatibility of polymer materials.13 The other site,
subjacent to the buccal mucosa, is the intended functional locale for the artificial salivary gland device.
This site differs considerably from those previously examined with these polymers in several important
respects. The epithelium of oral mucosa, including the keratinized regions, is much more permeable to
a variety of biological agents to which it is frequently exposed (e.g., microbial, food-associated, envi-
ronmental), and is richer in Langerhans cells, than is that of skin.14,15 The oral mucosa is constantly
bathed in saliva, while the skin is rarely moistened. Importantly, this bathing fluid can facilitate retro-
grade access of antigens to, and processing by, minor salivary glands and other epithelial cells.16 The
intraoral environment also gives rise to a microbial population that is different from, and much richer
than, that of skin.17
Additionally, the tissue beneath the buccal mucosa differs significantly from the tissue subjacent to
the skin on the back because it is a target site for the mucosal immune system. The mucosal immune
system is separate from its systemic counterpart, with distinct functions in host defense and differences
in major effector mechanisms.18–20 For example, at mucosal surfaces the principal antibody present is
secretory IgA, while the major immunoglobulin in serum is IgG. Mucosal CD41 (T helper) lympho-
cytes reflect a bias towards the production of Th2 (e.g., interleukins-4, -5, -6 and -10), versus Th1 (in-
terleukin-2 and interferon-g) cytokines.21,22 Further, mucosal-associated lymphoid cells tend to recir-
culate within the mucosal system, reflecting a homing mechanism mediated via the differential
expression of requisite attachment molecules by postcapillary venules.20,23,24
Thus, host responses at sites subjacent to skin and mucosa have the potential to differ in several im-
portant respects. Since previous work in which polymers were placed at sites subjacent to the skin on
the back might not identify tissue reactions at sites subjacent to oral mucosa, it seemed prudent to ex-
amine both of these regions through the present experimental design. For these studies, Balb/c mice
were chosen as the in vivo experimental model, because there is extensive information on their genetic
and immunologic characteristics, as well as considerable experience with their use in tissue engineer-
ing and gene transfer studies.25–27 In the present study, we examined host tissue responses using an im-





Fabrication of PLLA tubes
Hollow tubes of PLLA (Resomer L206; B.I. Chemicals Inc., Petersburg, VA) were formed by a two-step
process. Porous films of the polymers were first fabricated, and thereafter were formed into hollow tubes,
using modifications of methods reported previously.12 Briefly, to fabricate porous films, the polymer was
dissolved in chloroform yielding a 1.56% solution (w/v). An 8-mL aliquot of this solution was cast into a
5-cm glass Petri dish covered with a sheet of aluminum-backed tape (Cole Parmer, Chicago, IL). Sieved
sodium chloride crystals (150–250 mm in diameter) were dispersed evenly over the solution (0.375 g
NaCl/dish), and the chloroform was allowed to evaporate at room temperature. A polymer film with en-
trapped NaCl particles resulted. The salt particles were leached out of the film by immersion in one liter
of deionized water for 24 h at room temperature with constant shaking. This procedure yielded a highly
porous, thin membrane. Sections were cut from these films and rolled around a 22-gauge needle. The sur-
faces of the films that were adjacent to the aluminum-backed tape during preparation were always placed
adjacent to the needle when fabricating tubules. The overlapping ends of the film were sealed together by
briefly exposing one edge to chloroform, and manually pressing the overlapping ends together. This pro-
cess produced tubes ,3 mm long, with an inner diameter of ,0.5 mm (Fig. 1). Tubes were placed under
vacuum to remove residual solvent and sterilized by g-irradiation.
Fabrication of PGA tubes spray-coated with PLLA
PGA fibers (Albany International, Mansfield, MA; approximately 12 mm in diameter) were assembled
into 2-mm-thick nonwoven arrays. These exhibited a bulk density of 50 mg/mL, a porosity of ,97%, a
crystallinity of 57%, and an inherent viscosity of 1.23 dL/g following processing. The residual monomer
content was ,0.3%. Sections of the PGA nonwoven mesh were sealed together around a 22-gauge needle,
as above, by briefly spraying one end with a 5% solution (w/v) of PLLA (B.I. Chemicals) in chloroform.
PGA arrays were then coated with PLLA (Mw 102,000) to stabilize the arrays and to maintain their shape
following implantation.28 The PLLA was only applied to the external side of the PGA, and the thickness
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FIG. 1. Photograph of a tubular device fabricated from poly-L-lactic acid (top left, cross section; top right, longitu-
dinal view).
of PLLA coating was 20–50 mm. While still wrapped about the needle, the mesh was held at a distance of
1.5 ft and sprayed uniformly with the PLLA solution for 10 sec. The resulting tubes of PGA/PLLA were
,3 mm long, with an inner diameter of ,0.5 mm. These tubes were placed under vacuum to remove re-
sidual solvent and sterilized by g-irradiation.
Animals
One hundred and twenty-four female Balb/c mice (8 weeks old) were included in this study. All animals
were treated according to procedures approved by the National Institute of Dental and Craniofacial Re-
search Animal Care and Use Committee, and were monitored for any signs of distress. Mice were randomly
assigned to seven groups. A zero-time untreated control group (n 5 4) was used to generate normal clini-
cal chemistry and hematology data for this cohort. The remaining six groups consisted of PLLA implant,
PGA/PLLA implant, and sham-operated mice, with surgical sites at either the back or cheek areas. Five
time points were assessed (1, 3, 7, 14, and 28 days), and there were four animals/time point/group. Thus,
for each experimental and sham-operated group, 20 mice were studied (total 5 120). Animals were allowed
to acclimate for 1 week in our facility before any experimental manipulations were performed. Anesthesia
was induced with an intramuscular injection of a mixture of ketamine chloride (60 mg/kg) and xylazine (5
mg/kg) as previously described.29
Implantation procedure
The back or right cheek area was shaved and disinfected with iodine solution. Thereafter, a small skin
incision was made (,5 mm long), and a pocket was created by blunt dissection. Tubes then were implanted
via these skin incisions either subcutaneously in the mid-portion of the back or subjacent to the buccal mu-
cosa, that is, the oral mucosal lining of the cheek. Extreme care was taken not to perforate or otherwise
damage the buccal mucosa. The incision was closed using 6-0 coated Vicryl absorbable sutures (Ethicon
Inc., Somerville, NJ; Fig. 2). It is important to recognize that implantation of tubules beneath the cheek and
adjacent to the buccal mucosa in the manner described here does not reflect the intended manner of deliv-
ery of an artificial gland device clinically. Ideal placement would be performed intraorally via an incision
in the buccal mucosa. For the present study, this was not done because of (i) the small size of the opening
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FIG. 2. Illustration depicting the approximate site of tubular device implantation in the back or in the right cheek of
a recipient mouse. Photographic inserts show actual implantations at the two tissue target sites.
between the mouse maxilla and mandible, making such an operative procedure difficult and (ii) our con-
cern that it would be difficult to prevent infection of a significant intraoral wound site in these animals.
At the conclusion of each time point, blood was obtained from the animals by retro-orbital bleeding. An-
imals then were euthanized by carbon dioxide inhalation. In order to have adequate volumes for all analy-
ses, blood or serum samples from all animals in each separate group, for each separate time point, were
pooled. Thus, all clinical chemistry and hematology data reported are average values for the indicated time
point within a group. A complete blood count with differential and conventional serum chemistry analyses
were performed. In addition, as noted earlier, we utilized another group of age-matched animals, not sub-
jected to any experimental maneuver except obtaining blood, as a control group for hematological and chem-
istry analyses. Although only representative clinical chemistry results are presented, the following analyses
were performed: uric acid, calcium, phosphorous, sodium, potassium, chloride, bicarbonate, magnesium,
alkaline phosphatase, total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), to-
tal protein, albumin, cholesterol, glucose, lactate dehydrogenase, creatinine, urea nitrogen, creatine kinase,
triglycerides, amylase, lipase, and gamma-glutamyltransferase.
Histologic examination
A block of tissue surrounding the implant or sham-operated site, including skin, underlying muscle, and,
in the cheek sites, buccal mucosa, was excised from the euthanized animals with a scalpel and scissors. The
tissues were fixed immediately in Z-FIX (Anatech, Battle Creek, MI). After paraffin embedding, serial sec-
tions ,6 mm thick were cut and stained with either hematoxylin and eosin or Masson’s trichome connec-
tive tissue stain.30 Representative photomicrographs were taken using 35 mm Kodachrome 25 experimen-
tal slide film (Eastman Kodak Company, Rochester, NY).
RESULTS
All but three animals recovered readily from the implantation procedure. Of the three animals that died
postoperatively, two had implantations through the cheek adjacent to the buccal mucosa and one received
a tubule placed in the back. Two of the tubules implanted in these animals were constructed of PGA/PLLA,
and the remaining one was made of PLLA.
Clinical chemistry and hematology
Blood samples from mice at each time point were pooled together according to each experimental group
to provide sufficient sample volume for analyses. Normal values for this study, however, were obtained
from individual mice of this cohort that were untreated except for the collection of blood (Fig. 3). For most
analyses, there were no major differences seen between the sham-operated and implant groups for any of
the measures. Results of four representative analyses are summarized in Figure 3. Neutrophil levels were
elevated initially postimplantation of tubules subjacent to the buccal mucosa, above those seen in the sham-
operated mice, but returned to similar values by 28 days (Fig. 3A). Lactate dehydrogenase, a cellular en-
zyme whose serum levels reflect general tissue damage, was high initially in all experimentally manipu-
lated groups and thereafter (,14 days) decreased to low levels (Fig. 3B). The normal control values were
also high for this enzyme, likely reflecting trauma associated with the blood collection procedure. Creati-
nine (a general indicator of renal function) and aspartate aminotransferase (AAT; a general indicator of he-
patobiliary function) levels were similar in all groups (implanted and sham; Fig. 3C,D). Initial values of
AAT for all groups were high, likely reflecting the effects of anesthesia. In general, the results obtained
with mice receiving tubular implants, both PLLA and PGA/PLLA, in either the back or cheek adjacent to
the buccal mucosa were quite similar to each other.
Histologic analysis
PLLA and PGA/PLLA tubules elicited generally similar inflammatory responses at both tissue implan-
tation sites. Initially we observed a moderate to heavy collection of mostly neutrophils and scattered
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eosinophils, which gradually was replaced primarily by mononuclear cells (Fig. 4A–C). The chronology of
these inflammatory infiltrations was correlated with the elevations in blood neutrophil levels reported above.
Beginning at 14 days, the tubules attracted increasing numbers of epithelioid and multinuclear giant cells
(Fig. 4D). Over the experimental time course, this resulted in a considerable degradation of the PGA/PLLA
tubules (Fig. 4D) at both implant sites. Conversely, the PLLA tubules showed much less degradation over
this time, displaying a smooth or only slightly scalloped edge after 28 days (Fig. 4C). The sham-operated
sites developed inflammation that was much less intense and much shorter in duration, being essentially re-
solved after 14 days, with no epitheloid or giant cells being seen.
The skin (both sites) overlying several of the implants developed epithelial hyperplasia, with acanthosis,
hyperkeratosis and parakeratosis (Fig. 4E,F). These changes were absent or minimal in later specimens of
PGA/PLLA, in which the tubules had been partly digested and the inflammation diminished accordingly.
These findings suggest that the skin epithelial changes were a normal, transient response to the stimulus of
the underlying inflammation. Oral mucosal epithelium, when observed, appeared unchanged. However, the
oral epithelium was missing over areas with an inflammatory response to the implants, and in two places
a loose end occurred where the underlying normal tissue approached an inflamed area. This suggested that
the epithelium had a weak attachment to the lamina propria in areas of severe inflammation, and thus was
stripped off during excision and processing. In addition, we found that three tubules had broken through
the skin epithelium after implantation, that is, toward the surgical/tubule implant entrance site. No tubule
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FIG. 3. Representative hematological and clinical chemistry analyses of mice during the 28-day experimental time
course. In each panel, the left side represents average results from four mice with sham operations or with tubules im-
planted in their back, while the right side shows average results from four mice with sham operations or with implants
in their cheek. The black arrow in each panel represents the mean values obtained from four individual, nonsurgically
treated mice, and the shaded zone represents the standard deviation of those mean values. (A) Neutrophil levels in
whole blood. (B) Serum lactate dehydrogenase levels. (C) Serum creatinine levels. (D) Serum aspartate aminotrans-
ferase levels.
BIOCOMPATIBILITY OF TUBULAR SCAFFOLDS
655
FIG. 4. Representative photomicrographs of inflammatory responses to implanted tubules. (A) PGA/PLLA tubule 1
day after implantation in buccal mucosa, surrounded by inflammatory cells. Oral cavity side is at bottom, with a por-
tion of parotid gland (p) above. (B) Detail of inflammatory response near the implanted tubule in A, showing mostly
neutrophils but with scattered eosinophils (arrows). (C) PLLA tubule 28 days after implantation in the back. Despite
the inflammation, most of the tubule remains undegraded. Skin is at top. (D) PGA/PLLA tubule 28 days after im-
plantation beneath the buccal mucosa. The scattered remnants of the tubule are surrounded by epithelioid and foreign
body giant cells (arrows), as well as by lymphocytes, histiocytes, and neutrophils. (E,F) PGA/PLLA and PLLA tubules
(indicated by *) at 3 and 14 days after implantation in the mouth and back, respectively. Both tubules have breached
the skin surface, with the epithelium then having migrated part way (E) and completely (F) around the tubules, a pro-
cess appearing to lead toward exfoliation. The surface epithelium adjacent to the tubule in F is hypertrophic, with acan-
thosis and hyperkeratosis, but no dysplasia. Stains: hematoxylin and eosin (A–D), trichrome (E,F). Magnifications, 321
(A,C,E,F), 3310 (B), 380 (D).
was seen to extrude toward the buccal mucosa. In these specimens, the epithelium had migrated progres-
sively along the external faces of the tubules (Fig. 4E,F), a process that appeared to be leading to exfolia-
tion.
DISCUSSION
Our long-range objective is to utilize an artificial substratum to deliver organized epithelial cells into the
oral mucosa under conditions where the cells will thrive and secrete a saliva-like fluid. The resulting artifi-
cial salivary gland could supplement or otherwise enhance salivary secretions for individuals whose salivary
glands have been seriously and permanently damaged.31 In the present study, we have assessed the bio-
compatibility, inflammatory responses, and general systemic response characteristics of two candidate ma-
trices for such an artificial gland, PLLA and PGA/PLLA, in a frequently used animal model, Balb/c mice.
We found that the local tissue reaction to both polymers was more intense and prolonged than that which
was seen with the sham-operated mice. This elevated inflammatory reaction was observed at both implant
sites; i.e., in both the back and buccal mucosa. Systemic reactions were minimal, with no significant dif-
ferences generally found between animals with sham-operations and tubule implants. The local tissue re-
actions to PLLA and PGA/PLLA tubes were essentially identical, and the progression from acute to more
chronic inflammation was similar to that described in the literature.12,32–35 However, because of the animal
model tested, we were unable to implant the tubules in a manner directly comparable to that which we an-
ticipate would be done clinically. It will be necessary to perform preclinical animal studies in a model sub-
stantially larger than mice, despite the immunological and genetic value of the latter.
We did observe one potentially very important difference between the polymer implants: the much slower
rate of biodegradation of PLLA compared with PGA/PLLA at both implant sites in vivo. Such differences
in rates of degradation with these and other polymers have been reported in vivo.34,36 If the tubular scaf-
fold is essential to maintain substantive structural integrity for the early postplacement function of the pro-
posed artificial salivary gland, for example, to prevent collapse of the orifice or to maintain differentiation
of the lining cells, then the slower rate of degradation of PLLA tubules is advantageous. On the other hand,
it is conceivable that as the tubule is digested and removed, the salivary cells might become established in
a tubule-shaped monolayer on the granulation tissue bed left behind and join with the oral epithelium at the
orifice, providing for long-term function. In either case, however, the inflammatory response to both tubules
may be long and intense enough to damage or destroy the lining salivary cells, another potentially signifi-
cant concern.
Regardless of whether or not the salivary cells require permanent support of a tubular scaffold, their sat-
isfactory functioning will depend on the adequacy of their blood supply and an appropriate level of neu-
ronal stimulation. The oral mucosa is well supplied with blood vessels, and angiogenesis likely would be
enhanced by the initial inflammatory response. However, in irradiated tissue it may prove necessary to fa-
cilitate angiogenesis37 adjacent to implanted tubules, because the vasculature may be greatly reduced by
endothelial cell death and by subsequent scarring.31 Innervation may be more difficult to attain, particularly
in the irradiated fibrotic gland in the absence of a neurotrophic stimulus.38
A further consideration with irradiated tissues is the timing of clinical implantation of the device. Fol-
lowing irradiation, an oral mucositis often develops.39 During this period, the oral mucosa can be erythe-
matous, ulcerated, and extremely painful. Following completion of radiotherapy, mucosal healing promptly
commences. Thus, optimal timing for intraoral implantation of an artificial salivary gland likely would be
after resolution of the mucositis (4–6 weeks postirradiation).
In addition, it must be emphasized that the tubules implanted here were devoid of cells. All of our pre-
vious analyses of cell and matrix protein interactions with PLLA and PGA were performed in tissue cul-
ture with allogeneic graft cells in the absence of any host inflammatory response. Obviously, it is critical
to examine such interactions under in vivo conditions.40 However, if allogeneic cells were employed in the
device, it would likely lead to an additional immune response directed toward the cells. This could be ob-
viated by the use of autologous epithelial cells. The ability to grow and maintain primary cultures of sev-
eral salivary epithelial cell types has been achieved with rat glands.41,42 Clearly, an important next step in
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the development of the envisioned device would be to study the growth of primary epithelial cells on poly-
mer substrata in vivo.
Normal wound healing involves migration of the surface epithelium along granulation tissue as it devel-
ops, undermining and ejecting the clot. An analogous type of process seems to have occurred in the three
specimens in which the tubule had breached the surface toward the surgical incision site on the skin. This
phenomenon may pose a significant problem for the envisioned artificial gland. However, similar problems
have already been managed in other intraoral operative situations, for example, surgical reduction of peri-
odontal pockets and prevention of exfoliation of dental implants. For example, in the latter circumstance,
the tight mechanical and biological interactions occurring between the bone and implant surfaces appear to
provide a barrier preventing epithelial migration apically, as long as the epithelium and supporting lamina
propria are ,2 mm thick, and there is little peri-implant inflammation.43 In the case of an artificial gland,
in order to provide a patent orifice through which fluid can flow, it will be critical to firmly secure the ori-
fice of the device to the buccal mucosa to prevent its ejection. Future studies will need to specifically ad-
dress this concern by implanting the device in a manner consistent with its intended clinical use.
The biodegradable polyesters PLLA, PGA, and their copolymers have been extensively used in bio-
medical applications, and their biocompatibility widely studied.44 These polymers have been commercially
available since 1970 as surgical sutures, as this was their first approved clinical use.11 They are also used
in dental and orthopedic surgical procedures as implantable biomaterials.45,46 More recently, these poly-
mers have been utilized as cell transplantation vehicles for tissue engineering.47 PLLA and PGA are typi-
cally considered biocompatible when tested by various in vivo or in vitro assays,44,48 although the major-
ity of biocompatibility testing to date has used subcutaneous implantation.13,34 The biocompatibility of these
polymers in the form of solid implants has been questioned in certain orthopedic applications,45 which may
be related to local acidosis resulting from device degradation. Furthermore, these polymers in micropartic-
ular form can be used to carry antigens, and they appear particularly useful for oral mucosal immuniza-
tion.49–51 The breakdown of both PLLA and PGA/PLLA as shown herein adjacent to the oral mucosa, along
with the potential for associated damage to the lining graft cells, could provide a source for local mucosal
immune challenge that must be addressed in the future.
In conclusion, we believe that the results presented here represent an important step toward understand-
ing the potential complications following placement of an artificial salivary gland subjacent to the oral mu-
cosa. However, future studies in developing this device clearly require that several problems identified by
us herein be addressed in a more suitable animal model system.
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